Edarbyclor 40mg/12.5mg 28 tablets — Made in Ireland — Free Delivery

Treating hypertension to lower blood pressure:

- in patients whose blood pressure will be adequately controlled by monotherapy;

- as initial therapy for patients requiring combined AD.

- hypersensitivity to the active substance or other components of the preparation

- anuria

- treatment-resistant hypokalemia, hypercalcemia, hyponatremia

- severe violations of the liver and kidneys (creatinine clearance <30 ml / min);

- cholestasis, obstruction of the bile ducts;

- pregnancy and lactation;

- do not use together with aliskiren-containing agents in patients with diabetes mellitus;

- childhood;

- contraindicated in women planning pregnancy.

active ingredients: azilsartan medoxomil, chlorthalidone.

1 tablet contains azilsartan medoxomil potassium 42.68 mg (equivalent to 40 mg azilsartan medoxomil) and chlorthalidone 12.5 mg

excipients: mannitol (E 421), microcrystalline cellulose, fumaric acid, sodium hydroxide, hydroxypropylcellulose, crospovidone, magnesium stearate, hypromellose 2910, talc, titanium dioxide (E 171), iron oxide red (E172), polyethylene glycol 8000, gray ink F1 .

EdarbiClor® is intended for oral use, the tablets can be taken with or without food.

The recommended starting dose for adults is 1 tablet (40/12.5 mg) once daily. The antihypertensive effect is manifested mainly within 1-2 weeks of treatment. After 2-4 weeks of treatment, the dose, if necessary, can be increased to 40/25 mg in order to achieve the target level of blood pressure.

The use of the preparation EdarbiClor® in doses of more than 40/25 mg is not advisable.

EdarbiClor® can be used to provide additional blood pressure lowering in patients whose hypertension is not well controlled on monotherapy with an angiotensin II receptor antagonist or diuretic. Patients who are not adequately controlled while taking azilsartan medoxomil at a dose of 80 mg can achieve an additional clinical reduction in systolic / diastolic blood pressure by 13/6 mm Hg. Art. after prescribing EdarbiClor® at a dose of 40/12.5 mg. Patients who are not well controlled with chlorthalidone 25 mg may achieve an additional clinical blood pressure reduction of 10/7 mmHg. Art. after prescribing EdarbiClor® at a dose of 40/12.5 mg.

EdarbiClor® can be used as first-line therapy if the patient needs complex therapy to achieve the target blood pressure level.

Patients for whom doses of the individual components of the preparation (azilsartan medoxomil and chlorthalidone) have already been selected can receive an appropriate dose of EdarbiClor® in return.

If necessary, EdarbiClor® can be administered together with other antihypertensive preparations.

Before starting treatment with EdarbiClor®, it is necessary to correct hypovolemia, if present, especially in patients with impaired renal function and in patients receiving high doses of diuretics (see section "Peculiarities of use").

Patients who experience dose-limiting adverse reactions to chlorthalidone can be prescribed EdarbiClor®, starting with a low dose of chlorthalidone (see section "Peculiarities of use").

Children.

The preparation EdarbiClor® is not prescribed for children, since data on the safety and efficacy of use in children (under the age of 18 years) are not available.